Path to TFR: Role of immune system in CML

[SY4-4] Immunotherapy of CML and immunological characteristics of therapy response

Satu Mustjoki (Hematology Research Unit, University of Helsinki, Finland)

Dr. Satu Mustjoki, MD, PhD is a professor of Translational Hematology at the University of Helsinki, Finland. She received her medical degree (1997) and PhD degree (2001) at the University of Helsinki, after which she did her specialty degree in Clinical Chemistry (laboratory hematology).Satu Mustjoki started her own research group in 2008 at the Helsinki University Hospital and her research experience includes basic and applied cancer research on leukemia and hematopoietic stem cells, cancer cell invasion, tumor immunology, and molecular genetics. She has also led several translational immunological biomarker studies in conjunction with the international clinical trials. Her current research interests focus both on tumor immunology and on the molecular mechanisms of T-cell malignancies and associated autoimmune disorders. This stems from her group’s recent discoveries of somatic mutations in the STAT3 gene in patients with lymphoproliferation and autoimmune disorders (N Engl J Med, 2012). Currently Satu Mustjoki is leading the Hematology research unit (www.helsinki.fi/hematology) at the University of Helsinki. Her group consists of 24 members involving both basic and clinical scientists in hematology and immunology. In 2015 she received a 5-year ERC Consolidator Grant, which relates to molecular mechanisms of autoimmune disorders. Dr Mustjoki has more than 100 publications in international peer reviewed journals, such as N Engl J Med, Nat Gen, Nat Commun, Blood, and Leukemia.